强化达标治疗策略在中轴型脊柱关节炎中的疗效:TICOSPA试验
TICOSPA试验是一项开放标签、实用性、整群随机对照研究,比较强化达标治疗(TC/T2T)与常规护理(UC)在中轴型脊柱关节炎(axSpA)患者中的效果。主要结局ASAS-HI改善≥30%的比例在TC/T2T组为47.3%,UC组为36.1%,差异无统计学意义;但多项次要疗效结局倾向于TC/T2T,安全性相似,且从社会角度具有成本效益优势。
要点
- TC/T2T每4周随访并依据预设方案强化治疗至ASDAS<2.1,主要结局未显著优于UC。
- 多项次要疗效结局在TC/T2T组更常见,但并非均达到统计学显著。
- 两组安全性相似,TC/T2T从社会角度可节省€472并增加0.04 QALY。
核心结论
- TC/T2T在主要结局上未显著优于UC,但多项次要疗效结局倾向于TC/T2T,安全性相似,且从社会健康经济学角度有利。
研究设计与样本
- 实用性、前瞻性、整群随机、对照、开放标签、为期1年的试验(NCT03043846),18个中心按1:1随机化。
- 纳入符合ASAS axSpA标准、ASDAS≥2.1、非甾体抗炎药治疗非最佳且未使用过生物制剂的患者,共160例(每组80例)。
主要发现
- 主要结局ASAS-HI改善≥30%的比例在TC/T2T组为47.3%,UC组为36.1%,差异无统计学意义。
- 所有次要疗效结局在TC/T2T组更常见,但并非均具有统计学显著性。
- 两组安全性相似。
- 从社会角度,TC/T2T相比UC额外获得0.04 QALY,并节省€472。
关键数值与推荐
- TC/T2T组每4周随访,依据预设策略强化治疗直至达到目标(即ASDAS<2.1);UC组每12周随访,由风湿科医生酌情治疗。
临床怎么用
- 对于活动性axSpA且未使用过生物制剂的病人,可考虑采用每4周随访的强化达标治疗策略,以期改善多项疗效结局并可能节省社会成本。
局限性
- 开放标签设计可能引入偏倚;主要结局未达统计学显著;样本量较小(160例);随访期仅1年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the benefits of a tight-control/treat-to-target strategy (TC/T2T) in axial spondyloarthritis (axSpA) with those of usual care (UC). METHODS: Pragmatic, prospective, cluster-randomised, controlled, open, 1-year trial (NCT03043846). 18 centres were randomised (1:1). Patients met Axial Spondylo Arthritis International Society (ASAS) criteria for axSpA, had an Ankylosing Spondylitis Disease Activity Score (ASDAS) ≥2.1, received non-optimal treatment by non-steroidal anti-inflammatory drugs and were biologic-naive. INTERVENTIONS: (1) TC/T2T: visits every 4 weeks and prespecified strategy based on treatment intensification until achieving target (ie, ASDAS <2.1); (2) UC: visits every 12 weeks and treatment at the rheumatologist's discretion. MAIN OUTCOME: Percentage of patients with a ≥30% improvement on the ASAS-Health Index (ASAS-HI). Other efficacy outcomes and adverse events were recorded. A health economic evaluation was performed. STATISTICAL ANALYSIS: Two-level mixed models were used to estimate efficacy outcomes. Cost-effectiveness was assessed by the incremental cost per quality-adjusted life-year (QALY) gained for TC/T2T versus UC. RESULTS: 160 patients were included (80/group). Mean (SD) age was 37.9 (11.0) years and disease duration was 3.7 (6.2) years; 51.2% were men. ASDAS at inclusion was 3.0 (0.7), and ASAS-HI was 8.6 (3.7). ASAS-HI improved by ≥30% in 47.3% of the TC/T2T arm and in 36.1% of those receiving UC (non-significant). All secondary efficacy outcomes were more frequent in the TC/T2T arm, although not all statistically significant. Safety was similar in both arms. From a societal perspective, TC/T2T resulted in an additional 0.04 QALY, and saved €472 compared with UC. CONCLUSION: TC/T2T was not significantly superior to UC for the primary outcome, while many secondary efficacy outcomes favoured it, had a similar safety profile and was favourable from a societal health economic perspective. TRIAL REGISTRATION NUMBER: NCT03043846.
引用
- Molto A, López-Medina C, Van den Bosch FE, et al. Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. Ann Rheum Dis. 2021. PMID: 33958325. doi:10.1136/annrheumdis-2020-219585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。